Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Tanimilast and Glycopyrronium in Healthy Subjects
NCT03004495Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in chronic obstructive pulmonary disease (COPD) comparing CHF5259 and CHF6001, CHF5259 + placebo and CHF6001 + placebo (3 arms). Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time 0 to 12h Post Dose at Steady State and Maximum Plasma Concentration at Steady State at Day 14. Started Jan 2016; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03004495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004495.